Impact of the COVID-19 Pandemic on the Diagnosis and Prognosis of Melanoma
Metadatos
Afficher la notice complèteAuteur
Martínez López, Antonio; Díaz Calvillo, Pablo; Cuenca Barrales, Carlos; Montero Vílchez, Trinidad; Sánchez Díaz, Manuel; Buendía Eisman, Agustín; Arias Santiago, Salvador AntonioEditorial
MDPI
Materia
Melanoma COVID-19 SARS-CoV-2 Pandemic
Date
2022-07-19Referencia bibliográfica
Martinez-Lopez, A... [et al.]. Impact of the COVID-19 Pandemic on the Diagnosis and Prognosis of Melanoma. J. Clin. Med. 2022, 11, 4181. [https://doi.org/10.3390/jcm11144181]
Résumé
Background: Early detection of melanoma is one of the main diagnostic goals of dermatologists
worldwide, due to the increasing incidence of the disease in our environment. However, the
irruption of the SARS-CoV-2 pandemic has posed a challenge to global healthcare, forcing systems
to focus their resources on the fight against COVID-19. Methods: Retrospective cohort study. The
exposed cohort were patients diagnosed with melanoma in the year after the general confinement
in Spain (15 March 2020) and the unexposed cohort were patients with melanoma diagnosed in
the previous year. Results: 130 patients were included. No differences were observed between
demographic characteristics in both cohorts. The mean Breslow of melanoma before the onset of the
pandemic was 1.08, increasing to 2.65 in the year after the onset of the pandemic (p < 0.001). On the
other hand, the percentage of melanomas in situ decreased from 38.96% to 16.98% in the year after
the declaration of the state of alarm in Spain. Conclusions: The SARS-CoV-2 outbreak has led to a
reduction in the early diagnosis of melanoma, with an increase in invasive melanomas with poor
prognosis histological factors. This could lead to an increase in melanoma-related mortality in the
coming years in our environment.